To evaluate the role of extended hepatectomy in locally advanced intrahepatic cholangiocarcinoma (ICC). Summary Background Data: ICC is a rare tumor which has to be clearly distinguished from hepatocellular carcinoma and extrahepatic bile duct carcinoma. It is believed that long-term survival can only be achieved by surgical resection. Methods: Between April 1998 and March 2003, 50 patients with locally advanced ICC (tumor involvement of more than 4 liver segments) underwent surgical exploration. Data were analyzed with regard to patients' characteristics, intraoperative details, pathologic findings, and outcome measured by tumor recurrence, treatment of recurrence, and survival. Results: Resectability rate was 27 of 50 (54%). There were 19 extended right and 8 extended left hepatectomies. In addition, in 16 patients the following 29 procedures were performed: resection of hilar bifurcation (n ϭ 12), partial resection of diaphragm (n ϭ 6), partial resection of vena cava (n ϭ 4), resection and reinsertion of left liver vein (n ϭ 1), portal vein resection (n ϭ 5), resection and reconstruction of right hepatic artery (n ϭ 1). Complete tumor removal (R0-resection) was achieved in 16 patients. In 11 cases, there was microscopic tumor at the cutting margin (R1-resection). Following resection, the overall 1-and 3-year-survival rates were 69% and 55%. After R1-resection and explorative laparotomy, median survival was 5 and 7 months, respectively. Following R0-resection, the calculated median survival and 1-and 3-yearsurvival rates are 46 months, 94% and 82% (P ϭ 0.0039; log-rank test). Tumor recurred in 6 of 16 patients, and so far 2 patients died of recurrence 28 and 46 months after operation.
C holangiocellular carcinomas (CCC) are tumors arising from either the distal or proximal extrahepatic duct including the hilar bifurcation or from the intrahepatic ducts. It is currently accepted that each location of CCC represents an individual tumor entity with a different natural history, clinical presentation, and different prognosis. [1] [2] [3] Intrahepatic CCC (ICC) is less frequent than proximal or distal extrahepatic bile duct carcinoma, but it is the second common primary liver tumor after hepatocellular carcinoma. ICC accounts for about 10% of primary liver malignancies in Western countries but with increasing incidence during the past years. [3] [4] [5] Due to its intrahepatic localization, early symptoms are rare, and the majority of patients presents with advanced and often already extrahepatic tumors. In general, prognosis is very poor, with a reported median survival usually below 6 to 9 months after diagnosis in the majority of patients. 6 -8 Not least due to these unfavorable data, there is still great reluctance and uncertainty regarding surgical therapy in large and advanced ICC, although during the past years several reports have addressed the general value of liver resection in this certain tumor entity. 6 -16 However, because of the rarity of this tumor little data exist on outcome, particularly after extensive liver surgery for ICC. Most of the earlier series evaluating surgical therapy for ICC are ham-pered by the often small number of patients and by the fact that data have been collected over time periods longer than 1 or 2 decades. In addition, some series also enrolled patients with mixed hepato-and CCC or even proximal bile duct carcinoma (Klatskin tumors). Thus, comparability of data is limited and conclusions regarding resectability and outcome are potentially inaccurate.
Since 1998, we have adopted an aggressive surgical management in the treatment of locally advanced but potentially resectable ICC. The purpose of this study is to analyze our current series of consecutive 50 patient undergoing surgery for ICC within the past 5 years to value the role of extensive surgery in this particular patient population.
PATIENTS AND METHODS
Between April 1998 and March 2003, a total of 50 patients (23 female and 27 male) with a median age of 62 years (range: 27 to 75 years) underwent surgical exploration for intended liver resection of locally advanced ICC (tumors involving more than 4 liver segments) (Fig. 1a) . The diagnosis of ICC was based on histology obtained either by pre-or intraoperative biopsy or by the resected specimen. Hilar cholangiocarcinoma, gallbladder carcinoma, or mixed hepato-/CCC, as well as patients with liver cirrhosis, were excluded from our analysis.
Preoperatively, diagnostic workup was performed to exclude an extrahepatic primary tumor or metastasis. This included abdominal ultrasound and CT scan, chest x-ray, and upper endoscopy, as well as colonoscopy. In addition, in selected patients endoscopic retrograde cholangiography or magnetic resonance imaging (MRI) was performed, depending on clinical presentation or special indication. Since August 2001, additional 3-dimensional CT-scan of the liver including volumetry was available on special request of the surgeon. Intraoperative ultrasound was routinely used in liver resection.
None of the patients undergoing liver resection was lost to follow-up. Data were completed by September 30, 2003 . Minimum follow-up was 6 months or until death. Patients' survival was calculated using the Kaplan-Meier method. Statistical analysis was performed by log-rank test; P Ͻ 0.05 was considered significant.
Data of the patients were analyzed retrospectively with regard to (1) patients' characteristics, including presenting symptoms, biochemical markers, and preoperative therapy; (2) operative details such as extension of liver resection, vascular occlusion, requirement of blood products, as well as postoperative complications; (3) pathologic findings, including surgical radicality and tumor staging; and (4) outcome measured by tumor recurrence, treatment of recurrence, and survival.
RESULTS

Patients' Characteristics
Patients' characteristics for the resection and exploration group are listed in Table 1 .
In 5 patients, ICC had been diagnosed by sonography at follow-up for other malignancies (n ϭ 2) or primary sclerosing cholangitis (n ϭ 3). Preoperatively, a tumor biopsy showing adenocarcinoma had been performed in 29 of 50 patients. Serum carbohydrate 19 -9 antigen (CA 19 -9) levels were available in 41 patients (24 of the resection group and 17 of the exploration group).
In 13 patients, intraductal stents had been placed to relieve jaundice. Two patients had already undergone treatment of ICC prior to extended liver resection. This included 1 chemoembolization 2 months and resection of segment VI Extended Hepatectomy for ICC 32 months before admission to our department, respectively. Resectability rate was 27 of 50 (54%); in 23 cases only an explorative laparotomy was possible due to disseminated intra-(n ϭ 12) or extrahepatic (n ϭ 11) tumor spread.
Resection Group Surgical Procedures
There were 19 extended right hepatectomies (Seg IV-VIII Ϯ I), 1 plus wedge resection of seg III, and 8 extended left hepatectomies (Seg II-V, VIII Ϯ I) with 1 additional wedge resection of seg VI (Fig. 1a, b) . Dissection of regional lymph nodes was routinely performed. In addition, in 16 patients the following 29 procedures were performed: resection of hilar bifurcation (n ϭ 12) or partially diaphragm (n ϭ 6), partial resection of the inferior vena cava (IVC) and reconstruction with venous allografts (n ϭ 3) or Gore-Tex prosthesis (n ϭ 1), resection and reinsertion of left liver vein (n ϭ 1), portal vein resection with end/end anastomosis (n ϭ 4) or by a venous allograft (n ϭ 1), resection of hepatic artery and interposition by autologous venous graft (n ϭ 1). Operative data are summarized in Table 2 .
Intraoperative Data
Liver resection was performed under hilar vascular occlusion in 8 of 27 and under total vascular exclusion of the liver in 7 of 27 cases. In 2 patients, a temporary end-to-side portacaval shunt or a femoroportoaxilliary venovenous bypass was used. One liver resection was performed under total vascular exclusion and in situ protection by hypothermic perfusion because of complex reconstruction of IVC and portal vein ( Fig. 2A, B ; Table 3 ).
A median transfusion of 2 units (range, 0 -12 units) of packed red blood cells was required.
Morbidity and Mortality
Three patients died within 30 days after operation (mortality rate 6%). There was 1 death after R0-resection, 1 after R1-resection, and 1 after exploration, respectively. Causes of death were pulmonary embolism (n ϭ 1) and multiorgan-failure (n ϭ 2), in 1 case because of repeated hepatic artery thrombosis after extended left resection plus resection and interposition of hepatic artery.
Postoperative morbidity was 36% for the entire 50 patients, 52% for the resection group and 17% for the patients undergoing exploration only (Table 4 ). In the 16 cases with hepatectomy plus additional vascular, diaphragmatic or hilar resection, morbidity was 9 of 16 (56%) compared with 5 of 11 (45%) in hepatectomies without extension of operation. There was 1 postoperative death in each of these 2 groups.
After resection, morbidity required reoperation in 6 and percutaneous intervention in 4 cases. After exploration, reoperation and placement of an intraductal stent was performed in 1 case each.
Pathology
Median tumor diameter was 10 cm (range, 5.5-18 cm). Tumor was solitary in 11 cases. Overall, there were 16 R0 resections and 11 R1 resections. Extension of operation (n ϭ 16) resulted in 9 R0 and 7 R1 resections. Safety margin was less than 1 cm in 6, more than 1 cm in 7, and not determined in 3 patients. Microvascular infiltration was detected in 15 cases (56%). In 6 of these patients (22%), there was also macrovascular tumor invasion of the caval vein (n ϭ 1), hepatic artery (n ϭ 2), major liver vein (n ϭ 1), and portal vein or main left or right portal venous trunk (n ϭ 5). Regional lymph node metastasis was found in 8 cases (30%). There was no tumor infiltration of any of the 12 removed hilar bifurcations.
Tumors were staged according to recent (fifth edition) and current UICC classification (sixth edition, 2002) (Tables 5 and  6 ). 17, 18 In stage I and stage II tumors (according to sixth edition), R0 resections could be achieved without exception. R1 resections (n ϭ 11) were associated with stage III tumors only (Table 5 ). In 9 of these 11 patients, all with a multifocal tumor, the cutting surface showed microscopic tumor invasion (Fig. 3) . In the other 2 cases, the resection margin of the portal vein or hepatic artery was tumor positive.
Survival and Recurrence
Following resection, there is a calculated 1-and 3-year survival rate of 69% and 55%. After R0-resection, currently 13 of 16 patients are alive at a median follow-up of 28 months (range, 0 -51 months) so far. In R0 resection, the calculated median survival is 46 months, and the calculated 1-and 3-year survival is 94% and 82%, respectively (Fig. 4) . In the patient with prior segmentectomy, total survival is now 76 months after first operation.
Tumor recurred in 6 of 16 patients between 4 months and almost 3 years after R0 resection. In all cases, ICC had been multifocal or with micro/macrovascular infiltration or with regional lymph node metastasis ( Table 7) . Treatment of 
recurrence consisted of repeated (palliative) liver resection (n ϭ 1), laser therapy (n ϭ 2), chemotherapy (n ϭ 2), and living related liver transplantation (LDLTx; n ϭ 1). Four of these patients are alive at 9, 20, 21, and 44 months after operation. The other 2 patients died 28 and 46 months after liver resection due to multifocal tumor spread. After R1 resection, 8 of 11 patients died within 1 year after operation. Due to poor physical condition, palliative chemotherapy was performed only in 3 patients. So far, median survival after R1 resection is 5 months (range, 0 -26 months) and the calculated 1-year survival 22%. Currently, 3 patients are alive at 6, 7, and 8 months after operation.
Statistical analysis showed a significantly better survival for R0 resection compared with R1 resection (P Ͻ 0.0039; log-rank test) (Fig. 4) .
Patients' Survival After R0 Resection According to Lymph Node Status
There were 4 R0 resections in nodal positive patients (1 postoperative death). Three patients are alive 7, 21, and 30 months after operation, with 1 recurrence (Table 5) .
Patients' Survival After R0 Resection According to Micro-or Macrovascular Infiltration
So far, median survival after R0 resection without microvascular infiltration (n ϭ 9) is 31 months versus 20 months in cases (n ϭ 7) with microvascular infiltration (P ϭ II  T2  N0  M0  IIIA  T3  N0  M0  IIIB  T1-3  N1  M0  IVA  T4  Any N  M0  IVB  Any T  Any N  M1  UICC Sixth edition  I  T 1  N 0  M 0  II  T2  N0  M0  IIIA  T3  N0  M0  IIIB  T4  N0  M0  IIIC  Any T  N1  M0  IV Any T Any N M1 0.35, n.s.). In the group with no vascular invasion, there was tumor recurrence in 2 of 9 patients versus 4 out of 7 patient after resection of tumors with vascular invasion, resulting in a significantly higher tumor-free survival in the first group (P ϭ 0.028) (Fig. 5) . The only patient after R0 resection of a tumor with macro-(and micro) vascular invasion died 46 months after resection (and 21 months after LDLTx) due to multifocal recurrence.
Patients' Survival After R0 Resection According to Solitary and Multifocal Tumor
Except 1 postoperative death, all patients (n ϭ 9) after R0 resection of a solitary ICC are alive, with a median survival of 30 months, with tumor recurrence in 2 cases so far. Multifocal tumors recurred in 4 of 7 patients. Median survival is currently 25 months.
Patients' Survival After R0 Resection According to Tumor Stage
So far, there is no tumor recurrence in stage I (n ϭ 5), with a median survival of 34 months, whereas in stage II, 2 of 3 patients developed tumor recurrence 8 and 17 months after resection. In stage III, 4 patients developed tumor recurrence, with 2 tumor-associated deaths. So far, median survival is 25 months (range 0 -46 months) after resection of stage III tumors.
Patients' Survival After R0 Resection According to Extension of Resection
Currently, 7 of the 9 patients after extended hepatectomy with additional vascular, diaphragmatic, or hilar resection are alive, with a median survival of 30 months. There had been 1 postoperative death. Tumor recurred in 3 of 8 patients, leading to 1 tumor-associated death 46 months after operation, so far.
In the group without extension of resection, in 3 of 7 patients tumor recurred. One patient died 28 months after resection; the others are alive at a median follow-up of 22 months so far.
Exploration Group
In 23 patients, ICC was irresectable due to disseminated intrahepatic (n ϭ 12) or extrahepatic tumor (n ϭ 11). At exploration, 1 gastrojejunostomy, 1 cholecystectomy, and 2 hepaticojejunostomies were performed. Palliative chemotherapy with various protocols, mostly based on 5-fluorouracil or cisplatin was performed in 13 of 22. Median survival is 7 months (range, 0 -19 months). So far, 15 patients have died due to their disease after a median of 7 months.
DISCUSSION
Our report with 27 extended hepatic resections in 50 patients undergoing surgical exploration for ICC over a 
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Extended Hepatectomy for ICC 5-year period is to our knowledge the largest contemporary series. Most important, the presented data with a calculated 3-year survival of 82% after R0 resection compared with a median survival of only 5 months and 7 months after noncurative resection or explorative laparotomy clearly outline that an R0 resection leads to a significant prolongation of survival, even in advanced ICC. In contrast, incomplete tumor removal does not provide any survival benefit, but patients bear the risks of major hepatic surgery. In our series, despite a very aggressive surgical attitude-even the need for complex vascular reconstruction (ie, at the in situ hypothermic perfused liver was not considered to be a contraindication)-resectability rate was low (54%), with only 32% R0 resections in the entire patient group. With regard to the poor outcome after exploration and in particular after R1 resection, the need for an exact preoperative assessment of resectability to avoid unnecessary laparotomy becomes obvious. Therefore, in addition to routine MRI or contrast-enhanced CT, probably including 3-dimensional reconstruction of the liver, we also have changed our policy, now starting with a minimally invasive access by laparoscopy and laparoscopic ultrasound to assess resectability. This approach has been shown to improve tumor staging of hepatobiliary malignancies, 19, 20 and in particular for ICC, Weber et al 16 could achieve a 27% reduction of explorative laparotomy. However, since liver resection offers the only chance for long-term survival, we still see a very broad indication for surgical exploration, taking into account associated morbidity.
Although surgical technique and perioperative management have been steadily improved, extensive hepatectomy still has a significant morbidity and mortality. Most series report a mortality rate below 5% in major liver surgery. 6 -7,10,15,16,21,22 In our series, the extent of resection and the amount of additional procedures such as vascular or biliary reconstructions exceed other reports by far. Therefore, looking exceptionally at data of extended hepatectomy in combination with biliary surgery-showing a mortality rate up to 10% or even more-our results of 7% mortality and 33% morbidity are acceptable. 8, 23, 24 Nevertheless, with an increased use of 3-dimensional CT, we hope to further reduce this complication rate.
In the presented series, extended liver resection was performed with curative intention in every case. However, in a substantial number of patients (41%) microscopic tumor was found at the cutting margin (R1 resection), mostly because of infiltration by small satellite lesion. Similarly, Cherqui et al 15 reported on a 36% margin involvement in a series of 19 mainly advanced and central ICC, most likely that in these patients there was already bilateral but undetected tumor at the time of resection. At present, intraoperative ultrasound is the standard procedure to visualize small intrahepatic focal lesion. 25 Therefore, after an initial intraoperative ultrasound to assess resectability, we now perform a repeated sonography of the resection line and future liver remnant after ligation of hilar structures and major liver veins to increase the chance to detect satellite lesions. It needs to be investigated whether intraoperative ultrasound in combination with contrast agent infusion can reduce the number of incomplete resections by a better visualization of small, otherwise undetectable lesions. 26, 27 In recent years, in addition to R0 resection numerous prognostic factors have been investigated. In several studies, the negative prognostic influence of tumor positive lymph nodes, micro-or macrovascular infiltration, as well as multifocal tumor growth has been shown. 7,8,10,11,15,16,28 -30 However, the value of liver resection in the presence of 1 or several of these prognostic factors, especially in case of lymph node involvement, still remains a matter of debate. 30 -32 In the presented series, the survival of (only) 3 patients with tumor-positive lymph nodes but potentially curative resection has exceeded the median survival of the R1 or explorative laparotomy group by far. The same is true for other prognostic factors like multifocal tumor growth or microscopic vascular invasion, although the recurrence-free survival is significantly shorter in cases with vascular invasion. Macrovascular infiltration was associated with a high rate of R1 resection, which in most cases was not related to the vascular invasion but to the presence of multifocal tumor, but in the only case of complete tumor removal, survival also was much better than after incomplete resection.
There is no doubt that the number of our patients is by far too small to draw valid conclusions or to do further statistical analysis. However, based on the presented data we do not consider the presence of any of these prognostic factors as a contraindication to liver resection if a complete tumor removal is possible.
Recently, a new TNM classification (the sixth edition) of the UICC has come into effect, leading to significant changes in the classification of primary hepatic tumors (Tables 5 and 6). 18 It is remarkable that in our series tumor recurred in more than half of the patients with stage II and III tumors, mainly those with vascular invasion, but not in patients after resection of stage I tumors. This is an interesting finding because it may help to identify patients at risk for recurrence, thus being candidates for adjuvant therapy.
During the past years, several retrospective studies have addressed the value of liver resection in ICC (Table 8) . As already outlined, comparison of survival data in literature is difficult due to the often inhomogenous selection criteria and the small number of cases or the long time period over which data have been collected. Furthermore, surgical radicality and tumor staging according to the UICC classification have not always been considered. Similar to our report, Weber et al, 16 Roayaie et al, 10 as well as Cherqui et al 15 did also enroll exclusively ICC in an analysis of 33, 18, and 14 resections, but no further tumor classification according to UICC was done. After resection, they found a median survival of 45 months, 43 months, and 27 months, respectively (Table 8) . In their analysis, the portion of extended hepatectomies ranged between 45% and 69%. These data already point out that remarkable long-term results can be achieved by an aggressive surgical therapy. In our series, there was 100% extended hepatectomies, which probably indicates even more advanced tumors. Therefore, our results do not only confirm these data of literature but do encourage also extended hepatectomy with complex vascular and biliary reconstruction, even in advanced or centrally located ICC. With this approach, we at least could provide a 3-year survival in about 25% of all of our patients undergoing surgery for locally advanced ICC (82% in 16 R0 resections out of 50 patients).
In contrast to resection, results of liver transplantation (LTx) for ICC have been very disappointing. [33] [34] [35] In the 3 largest single-center series with a total of 60 patients, survival at 1 year ranges between 22% and 70% and at 3 years between 0% and 39%. 8, 14, 36 Further analysis shows favorable outcomes mainly for small tumor size, single tumors, and absence of other organ invasion or lymph node metastases, corresponding to UICC stages I and II. However, in these tumors results of liver resection are at least similar, if not superior, to these data. 8, 12 Therefore, with regard to donor organ shortage these patients should not be treated by LTx unless severe concomitant liver disease (ie, advanced primary sclerosing cholangitis or liver cirrhosis) prevents liver resection. We performed 1 living related liver transplantation for intrahepatic recurrence 25 months after liver resection. This patient survived for another 21 months. Similarly, Cherqui et al 15 reported on 2 patients with disease-free survivals of 25 and 31 months after LTx, one for intrahepatic recurrence after resection and the other for primarily irresectable ICC, which had had a constant tumor size for almost 1 year prior to LTx. These data show that LTx probably may be considered in highly selected patients with limited intrahepatic recurrence or slowly growing unresectable ICC.
In conclusion, the presented results outline that an R0 resection leads to a significantly prolonged survival in locally advanced but not metastatic ICC. In particular, in solitary tumors without vascular invasion (UICC stage I, sixth classification), there is a major chance for long-term survival and cure. Since resection offers the only chance for cure, there is even an indication for extended liver resection in combination with complex vascular or biliary reconstruction. In contrast, the poor prognosis after explorative laparotomy or R1 resection does not justify palliative liver resection but underlines the need for an improved preoperative assessment of resectability, as well as an aggressive intraoperative approach to achieve complete tumor removal.
